Low-grade glial tumors: The experience of an oncology hospital in Türkiye

Ceylan, Serdar; kertmen, neyran; Yazici, Gozde; Kars, Ayşe

doi:10.32552/2023.ActaMedica.899

Low-grade glial tumors: The experience of an oncology hospital in Türkiye

Serdar CEYLAN, (Hacettepe Üniversitesi Tıp Fakültesi, Dahiliye Anabilim Dalı, Ankara, Türkiye)

Neyran KERTMEN, (Hacettepe Üniversitesi Kanser Enstitüsü Medikal Onkoloji Anabilim Dalı, Ankara, Türkiye)

Gözde YAZICI, (Hacettepe Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, Ankara, Türkiye)

Ayşe KARS (Hacettepe Üniversitesi Kanser Enstitüsü Medikal Onkoloji Anabilim Dalı, Ankara, Türkiye)

Acta Medica

19 7

Yıl: 2023 Cilt: 54 Sayı: 2 Sayfa Aralığı: 151 - 156 Metin Dili: İngilizce DOI: 10.32552/2023.ActaMedica.899 İndeks Tarihi: 23-07-2023

Low-grade glial tumors: The experience of an oncology hospital in Türkiye

Öz:

Objective: Several factors are important in the prognosis of low grade gliomas, besides genetic changes. The present study aims to examine the effect of other factors on prognosis except for genetic changes in low grade gliomas (LGGs). Materials and Methods: Patients diagnosed with “brain malignant neoplasm”who were referred to Hacettepe University Oncology Hospital were screened. Among these patients, 148 patients with a supratentorial low grade gliomas whose data are completely available were included. Patients were followed for at least five years after diagnosis or death within this period. Results: Mean age of diagnosis was 36.2±10.7 years, and 52.7% of patients (n=78) were females, Most common subtype was oligodendroglioma (n=86, 58.1%). Sixty-two of patients relapsed (41.9%). The 5-year mortality rate was 35.1% (n=52). Kaplan-Meier analysis of the variables, the only difference was between histopathological subtypes (p=0.03). Astrocytoma histology was related to wporse prognosis. Cox regression analysis of factors affecting 5-year mortality, advancing age (HR: 1.03, 95% CI: 1.00-1.06, p=0.03), astrocytoma (HR: 2.59, 95% CI: 1.35-4.98, p=0.004) and oligoastrocytoma (HR: 2.13, 95% CI: 1.02-4.43, p=0.04) were identified to increase the mortality risk. Conclusion: The age of the patients and the histopathologic subtype of the tumor must be taken into consideration during the follow-up and treatment of low grade gliomas.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

[1] Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97-109.
[2] Oberheim Bush NA, Chang S. Treatment strategies for low- grade glioma in adults. J Oncol Prac. 2016; 12: 1235-41.
[3] Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases. J Neurosurg. 2013; 118: 1157-68.
[4] Youland RS, Schomas DA, Brown PD, Parney IF, Laack NN. Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience. J Neurooncol. 2017; 133: 339-46.
[5] Sepúlveda-Sánchez J, Langa JM, Arráez M, et al. SEOM clinical guideline of diagnosis and management of low- grade glioma. Clin Transl Oncol. 2018; 20: 3-15.
[6] Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015; 372: 2481-98.
[7] Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low- grade gliomas in adults. J Neurosurg. 2008; 109: 817-24.
[8] Pignatti F, Van Den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low- grade glioma. J Clin Oncol. 2002; 20: 2076-84.
[9] Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016; 374: 1344-55.
[10] Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131: 803-20.
[11] Komori T. Update of the 2021 WHO classification of tumors of the central nervous system: adult diffuse gliomas. Brain Tumor Pathol. 2023; 40: 1-3.
[12] Stubblefield MD, O’Dell MW. Synopsis of Clinical Oncology. 1st Ed. New York; Demos Medical Publishing, 2010: 259-69
[13] Sanai N, Chang S, Berger MS. Low-grade gliomas in adults: a review. J Neurosurg. 2011: 1-18.
[14] Kumthekar P, Raizer J, Singh S. Low-grade glioma. Cancer Treat Res. 2015; 163: 75-87.
[15] Youland RS, Khwaja SS, Schomas DA, Keating GF, Wetjen NM, Laack NN. Prognostic factors and survival patterns in pediatric low-grade gliomas over 4 decades. J Pediatr Hematol Oncol. 2013; 35: 197-205.
[16] Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low- grade glioma. J Clin Oncol. 2002; 20: 2076-84.
[17] Lin Z, Yang R, Li K, et al. Establishment of age group classification for risk stratification in glioma patients. BMC Neurol. 2020; 20: 310.
[18] Cao J, Yan W, Zhan Z, Hong X, Yan H. Epidemiology and risk stratification of low-grade gliomas in the United States, 2004-2019: A competing-risk regression model for survival analysis. Front Oncol. 2023; 13: 1079597.
[19] Li X, Li R, Ren H, Liu H, Liu H. Predicting factors of tumor progression in adult patients with low-grade glioma within five years after surgery. Transl Cancer Res. 2021; 10: 1907-15.
[20] Kaloshi G, Psimaras D, Mokhtari K, et al. Supratentorial low-grade gliomas in older patients. Neurology. 2009; 73: 2093-98.
[21] Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. 2017; 19 (Suppl 1): v1-88.
[22] Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/ Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002; 20: 2267-76.
[23] McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low- grade gliomas. Neurosurgery. 2008; 63: 700-08.
[24] Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008; 26: 1338-45.
[25] Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012; 308: 1881-88.
[26] Jakola AS, Unsgård G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival and morbidity with a strategy of early resection as compared to watchful waiting. Acta Neurochir. 2013; 155: 2227-35.
[27] Wijnenga MM, MattniT, French PJ, et al. Does early resection of presumed low-grade glioma improve survival? A clinical perspective. J Neurooncol. 2017; 133: 137-46.
[28] Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016; 374: 1344-55.
[29] Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004; 22: 3133-38.
[30] Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997; 79: 1381-93.

APA	Ceylan S, kertmen n, Yazici G, Kars A (2023). Low-grade glial tumors: The experience of an oncology hospital in Türkiye. , 151 - 156. 10.32552/2023.ActaMedica.899
Chicago	Ceylan Serdar,kertmen neyran,Yazici Gozde,Kars Ayşe Low-grade glial tumors: The experience of an oncology hospital in Türkiye. (2023): 151 - 156. 10.32552/2023.ActaMedica.899
MLA	Ceylan Serdar,kertmen neyran,Yazici Gozde,Kars Ayşe Low-grade glial tumors: The experience of an oncology hospital in Türkiye. , 2023, ss.151 - 156. 10.32552/2023.ActaMedica.899
AMA	Ceylan S,kertmen n,Yazici G,Kars A Low-grade glial tumors: The experience of an oncology hospital in Türkiye. . 2023; 151 - 156. 10.32552/2023.ActaMedica.899
Vancouver	Ceylan S,kertmen n,Yazici G,Kars A Low-grade glial tumors: The experience of an oncology hospital in Türkiye. . 2023; 151 - 156. 10.32552/2023.ActaMedica.899
IEEE	Ceylan S,kertmen n,Yazici G,Kars A "Low-grade glial tumors: The experience of an oncology hospital in Türkiye." , ss.151 - 156, 2023. 10.32552/2023.ActaMedica.899
ISNAD	Ceylan, Serdar vd. "Low-grade glial tumors: The experience of an oncology hospital in Türkiye". (2023), 151-156. https://doi.org/10.32552/2023.ActaMedica.899

APA	Ceylan S, kertmen n, Yazici G, Kars A (2023). Low-grade glial tumors: The experience of an oncology hospital in Türkiye. Acta Medica, 54(2), 151 - 156. 10.32552/2023.ActaMedica.899
Chicago	Ceylan Serdar,kertmen neyran,Yazici Gozde,Kars Ayşe Low-grade glial tumors: The experience of an oncology hospital in Türkiye. Acta Medica 54, no.2 (2023): 151 - 156. 10.32552/2023.ActaMedica.899
MLA	Ceylan Serdar,kertmen neyran,Yazici Gozde,Kars Ayşe Low-grade glial tumors: The experience of an oncology hospital in Türkiye. Acta Medica, vol.54, no.2, 2023, ss.151 - 156. 10.32552/2023.ActaMedica.899
AMA	Ceylan S,kertmen n,Yazici G,Kars A Low-grade glial tumors: The experience of an oncology hospital in Türkiye. Acta Medica. 2023; 54(2): 151 - 156. 10.32552/2023.ActaMedica.899
Vancouver	Ceylan S,kertmen n,Yazici G,Kars A Low-grade glial tumors: The experience of an oncology hospital in Türkiye. Acta Medica. 2023; 54(2): 151 - 156. 10.32552/2023.ActaMedica.899
IEEE	Ceylan S,kertmen n,Yazici G,Kars A "Low-grade glial tumors: The experience of an oncology hospital in Türkiye." Acta Medica, 54, ss.151 - 156, 2023. 10.32552/2023.ActaMedica.899
ISNAD	Ceylan, Serdar vd. "Low-grade glial tumors: The experience of an oncology hospital in Türkiye". Acta Medica 54/2 (2023), 151-156. https://doi.org/10.32552/2023.ActaMedica.899